Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-05-30
2002-04-30
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S301000, C514S258100, C514S249000, C514S248000, C544S236000, C544S279000, C544S350000, C546S114000, C546S122000
Reexamination Certificate
active
06380209
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to certain heterocyclic amino substituted heteroaryl fused pyridines which selectively bind to GABAa receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating anxiety, sleep and seizure disorders, and overdoses of benzodiazepine-type drugs, and enhancing alertness. The interaction of heterocyclic amino substituted heteroaryl fused pyridines of the invention with a GABA binding site, the benzodiazepines (BDZ) receptor, is described. This interaction results in the pharmacological activities of these compounds.
2. Description of the Related Art
&ggr;-Aminobutyric acid (GABA) is regarded as one of the major inhibitory amino acid transmitters in the mammalian brain. Over 40 years have elapsed since its presence in the brain was demonstrated (Roberts & Frankel, J. Biol. Chem 187: 55-63, 1950; Udenfriend, J. Biol. Chem. 187: 65-69, 1950). Since that time, an enormous amount of effort has been devoted to implicating GABA in the etiology of seizure disorders, sleep, anxiety and cognition (Tallman and Gallager, Ann. Rev. Neuroscience 8: 21-44, 1985). Widely, although unequally, distributed through the mammalian brain, GABA is said to be a transmitter at approximately 30% of the synapses in the brain. GABA mediates many of its actions through a complex of proteins localized both on cell bodies and nerve endings; these are called GABAa receptors. Postsynaptic responses to GABA are mediated through alterations in chloride conductance that generally, although not invariably, lead to hyperpolarization of the cell. Drugs that interact at the GABAa receptor can possess a spectrum of pharmacological activities depending on their abilities to modify the actions of GABA.
The 1,4-Benzodiazepines, such as diazepam, continue to be among the most widely used drugs in the world as anxiolytics, sedative-hypnotics, muscle relaxants, and anticonvulsants. A number of these compounds are extremely potent drugs; such potency indicates a site of action with a high affinity and specificity for individual receptors. Early electrophysiological studies indicated that a major action of benzodiazepines was enhancement of GABAergic inhibition. Presently, those compounds possessing activity similar to the benzodiazepines are called agonists. Compounds possessing activity opposite to benzodiazepines are called inverse agonists, and the compounds blocking both types of activity have been termed antagonists.
The GABAa receptor subunits have been cloned from bovine and human cDNA libraries (Schoenfield et al., 1988; Duman et al., 1989). A number of distinct cDNAs were identified as subunits of the GABAa receptor complex by cloning and expression. These are categorized into &agr;, &bgr;, &ggr;, &dgr;, &egr;, and provide a molecular basis for the GABAa receptor heterogeneity and distinctive regional pharmacology (Shivvers et al., 1980; Levitan et al., 1989). The &ggr; subunit appears to enable drugs like benzodiazepines to modify the GABA responses (Pritchett et al., 1989). The presence of low Hill coefficients in the binding of ligands to the GABAa receptor indicates unique profiles of subtype specific pharmacological action.
With the discovery of the “receptor” for the benzodiazepines and the subsequent definition of the nature of the interaction between GABA and the benzodiazepines, it appears that the behaviorally important interactions of the benzodiazepines with different neurotransmitter systems are due in a large part to the enhanced ability of GABA itself to modify these systems. Each modified system, in turn, may be associated with the expression of a behavior. Depending on the mode of interaction, these compounds are capable of producing a spectrum of activities (either sedative, anxiolytic, and anticonvulsant, or wakefulness, seizures, and anxiety).
SUMMARY OF THE INVENTION
This invention provides novel compounds of Formula I which interact with a GABAa binding site, the benzodiazepine receptor.
The invention provides pharmaceutical compositions comprising compounds of Formula I. The invention also provides compounds useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Accordingly, a broad embodiment of the invention is directed to compounds of general Formula I:
wherein:
the C ring represents a thiophene, pyridine, pyrazine, pyridazine, or pyrimidine ring, each of which is optionally substituted independently with one or two groups selected from C
1
-C
6
alkoxy, C
1
-C
6
alkoxy, halogen, hydroxy, amino, mono- or di(C
1
-C
6
)alkyl amino, or trifluoromethyl;
W is aryl, heteroaryl, 2- or 3-thienyl, or 2-, 3-, or 4-pyridyl, each of which may be mono, di- or trisubstituted independently with halogen, hydroxyl, lower alkyl, lower alkoxy, amino, or mono- or dialkylamino where each alkyl portion is lower alkyl; or CONR
4
R
5
wherein R
4
and R
5
are the same or different and represent lower alkyl; and
R represents hydrogen, lower alkyl, hydroxy(C
1
-C
6
)alkyl, amino(C
1
-C
6
)alkyl, mono- or di(C
1
-C
6
)alkylamino(C
1
-C
6
)alkyl, alkoxy(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy, or aryl (C
1
-C
6
)alkyl; or
R represents CONR
1
R
2
where R
1
and R
2
are the same or different and represent, hydrogen or lower alkyl or NR, R
2
forms a ring having from 3-7, preferably 5-6, members.
These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. In other words, while the compounds of the invention all interact with GABAa brain receptors, they do not display identical physiological activity. Thus, these compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. For example, these compounds can be used to treat overdoses of benzodiazepine-type drugs as they would competitively bind to the benzodiazepine receptor.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds encompassed by the instant invention can be described by general Formula I set forth above or the pharmaceutically acceptable non-toxic salts thereof.
In addition, the present invention also encompasses compounds of Formula IIa and IIb
or the pharmaceutically acceptable non-toxic salts thereof wherein W and R are as defined above for Formula I; and R
a
is hydrogen, C
1
-C
6
alkoxy, C
1
-C
6
alkoxy, halogen, hydroxy, amino, mono- or di(C
1
-C
6
)alkyl amino, or trifluoromethyl.
Preferred compounds of Formula IIa and IIb are where W is aryl or heteroaryl mono or disubstituted independently with halogen, hydroxyl, lower alkyl, or lower alkoxy.
Other preferred compounds of Formula IIa and IIb are where R is hydrogen, lower alkyl.
Preferred R
a
groups include C
1
-C
3
alkyl, C
1
-C
3
alkoxy, hydroxy, dimethyl amino, diethylamino, ethylamino, chloro, fluoro and bromo. Particularly preferred R
a
groups are chloro, bromo, fluoro, methylethyl and amino.
The present invention also encompasses compounds of Formula III:
wherein W and R are as defined above for Formula I; and
A, B, C, and D are independently CR
3
, or nitrogen, provided that no more than two of A, B, C, and D are nitrogen simultaneously;
R
3
is hydrogen, alkyl, halogen, hydroxy, or lower alkoxy.
Other preferred compounds of the invention are encompassed by the following formulae:
where
R is as defined above for Formula I; and
W is aryl or 2-, 3-, or 4-pyridyl, each of which may be mono or disubstituted independently with halogen, lower alkyl, lower alkoxy, amino, or mono- or dialkylamino where each alky portion is lower alkyl, or CONR
4
R
5
wherein R
4
and R
5
are same or different and represent lower alkyl.
More preferred compounds of Formula IV are those where W is
wherein
R
6
is halogen, hydroxy, lower alkyl, lower alkoxy, amino, or mono- or dialkylamino where each alkyl portion is lower alkyl,
Cai Guolin
Liu Gang
Huang Evelyn Mei
McDonnell & Boehnen Hulbert & Berghoff
Neurogen Corporation
LandOfFree
4-(4-piperidylmethylamino) substituted heteroaryl fused... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-(4-piperidylmethylamino) substituted heteroaryl fused..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(4-piperidylmethylamino) substituted heteroaryl fused... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2825767